Oral Presentation
Idiopathic pulmonary fibrosis (IPF): treatment highlights
10:45
Extracorporeal membrane oxygenation for the treatment of acute exacerbation of interstitial lung diseases
S. Ohshimo(Hiroshima, Japan)
COI
1
11:00
Late Breaking Abstract - Six years experience of Pirfenidone treatment in IPF patients in Crete: Real life data
K. Karagiannis(Heraklion Crete, Greece)
COI
2
11:30
Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
U. Costabel(Essen, Germany)
COI
3
11:45
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients
L. Richeldi(Roma, Italy)
COI
4
12:00
Incidence of multiple progression events in patients with idiopathic pulmonary fibrosis (IPF) in the pooled CAPACITY and ASCEND trials
S. Nathan(Falls Church, United States)
COI
5
12:15
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON
B. Crestani(Paris, France)
COI
6
12:30
Effect of nintedanib on composite physiologic index (CPI) in idiopathic pulmonary fibrosis (IPF)
A. Wells(London, United Kingdom)
COI
7
. . .
